Check out our recent publication on how digital tools are increasingly being validated and used in neurological clinical trials!
Great interdisciplinary project with @LarsMasanneck@arieldora Pauline Gieseler and William Gordon!
New in @npjDigitalMed with @LarsMasanneck Pauline Giesleler @willjg & @rn_meuth: the growth of digital health technologies in neurology research 🤳📈📲🙌
+ data on how tech has changed over the last decade: motor/sleep/cognition tracking, adherence, caregiver support & more! 👇
The share of neurological clinical trials using #digitalhealth technologies has increased from <1% in 2010 to >10% in 2021.
What will it look like in another 11 years?
https://t.co/zEupLBBlKm
Neue DFG-Forschungsgruppe zu Untersuchungen zur Ambivalenz des AHR-Signalweges in Hautkrankheiten mit Beteiligung der Neurologie des UKD https://t.co/chsrs90II9
Die Europäische Kommission hat Efgartigimod die Zulassung für die Behandlung, zusätzlich zur Standardtherapie, von erwachsenen PatientInnen mit generalisierter Myasthenia gravis, die Anti-Acetylcholin-Rezeptor-Antikörper positiv sind, erteilt.